Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.

Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort C, Van M, Prager WJC, De Laere B, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, de Wit R, Lolkema MP, Mathijssen RHJ, Martens JWM, Sleijfer S.

J Mol Diagn. 2018 Feb 20. pii: S1525-1578(17)30419-1. doi: 10.1016/j.jmoldx.2018.01.008. [Epub ahead of print]

PMID:
29474983
2.

"Duodenal Adenocarcinoma Giving Rise to Rectal Metastasis" a Rare Disease with an Extremely Rare Metastatic Pattern.

Epskamp C, van Eijck CHJ, Sinke RHJA, Hamberg P.

J Gastrointest Cancer. 2018 Feb 2. doi: 10.1007/s12029-018-0066-7. [Epub ahead of print] No abstract available.

PMID:
29392602
3.

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

Belderbos BPS, de Wit R, Hoop EO, Nieuweboer A, Hamberg P, van Alphen RJ, Bergman A, van der Meer N, Bins S, Mathijssen RHJ, van Soest RJ.

Oncotarget. 2017 Nov 16;8(63):106468-106474. doi: 10.18632/oncotarget.22474. eCollection 2017 Dec 5.

4.

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJE, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJA, Koopman M.

Int J Clin Oncol. 2017 Dec 4. doi: 10.1007/s10147-017-1220-0. [Epub ahead of print]

PMID:
29204933
5.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

PMID:
29150561
6.

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.

Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S.

Mol Oncol. 2018 Jan;12(1):48-57. doi: 10.1002/1878-0261.12147. Epub 2017 Nov 17.

7.

Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.

Van Veggel M, Westerman E, Hamberg P.

Clin Pharmacokinet. 2018 Jan;57(1):21-29. doi: 10.1007/s40262-017-0565-x. Review.

PMID:
28667459
8.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

9.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
10.

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.

Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S.

Neoplasia. 2016 Nov;18(11):647-653. doi: 10.1016/j.neo.2016.08.007. Epub 2016 Oct 17.

11.

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, Bergman AM, Beeker A, van Halteren H, Ten Tije AJ, Zuetenhorst H, van der Meer N, Chitu D, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Clin Cancer Res. 2017 Apr 1;23(7):1679-1683. doi: 10.1158/1078-0432.CCR-16-2110. Epub 2016 Oct 4.

PMID:
27702823
12.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS).

Oncology. 2016;91(5):267-273. Epub 2016 Aug 20.

PMID:
27544669
13.

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S.

Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.

14.

Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer.

Manenschijn L, Hamberg P.

Acta Oncol. 2016 May;55(5):656-8. doi: 10.3109/0284186X.2015.1118657. Epub 2016 Apr 4. No abstract available.

PMID:
27046420
15.

Bullous fixed drug eruption in a patient with metastatic renal cell carcinoma induced by iodinated contrast during pazopanib treatment.

Epskamp C, Snels DG, Yo GL, Zuetenhorst HJ, Hamberg P.

Eur J Dermatol. 2016 Apr 1;26(2):207-8. doi: 10.1684/ejd.2016.2734. No abstract available.

PMID:
26905214
16.

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.

Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MP, Gratama JW, Foekens JA, Martens JW, Berns EM, Sleijfer S.

BMC Cancer. 2016 Feb 18;16:123. doi: 10.1186/s12885-016-2155-y.

17.

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

Kloth JSL, Hamberg P, Mendelaar PAJ, Dulfer RR, van der Holt B, Eechoute K, Wiemer EAC, Kruit WHJ, Sleijfer S, Mathijssen RHJ.

Eur J Cancer. 2016 Mar;56:101-106. doi: 10.1016/j.ejca.2015.12.019. Epub 2016 Feb 1.

PMID:
26841094
18.

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup.

Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22.

PMID:
26390914
19.

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH.

Pharmacogenomics J. 2016 Nov;16(6):519-524. doi: 10.1038/tpj.2015.66. Epub 2015 Sep 8.

PMID:
26345519
20.

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13.

PMID:
26278646
21.
22.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
23.

Citation analysis of the 'Big Six' journals in Internal Medicine.

Van der Veer T, Baars JE, Birnie E, Hamberg P.

Eur J Intern Med. 2015 Jul;26(6):458-9. doi: 10.1016/j.ejim.2015.05.017. Epub 2015 Jun 9. No abstract available.

PMID:
26066401
24.

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.

Binkhorst L, Kloth JSL, de Wit AS, de Bruijn P, Lam MH, Chaves I, Burger H, van Alphen RJ, Hamberg P, van Schaik RHN, Jager A, Koch BCP, Wiemer EAC, van Gelder T, van der Horst GTJ, Mathijssen RHJ.

Breast Cancer Res Treat. 2015 Jul;152(1):119-128. doi: 10.1007/s10549-015-3452-x. Epub 2015 Jun 7.

25.

Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.

Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CH, Bolt-de Vries JB, Peeters DJ, Hamberg P, Seynaeve C, Jager A, de Jongh FE, Smid M, Dirix LY, Kehrer DF, van Galen A, Ramirez-Moreno R, Kraan J, Van M, Gratama JW, Martens JW, Foekens JA, Sleijfer S.

Cancer Lett. 2015 Jun 28;362(1):36-44. doi: 10.1016/j.canlet.2015.03.020. Epub 2015 Mar 19.

PMID:
25797316
26.

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.

Kloth JS, Binkhorst L, de Wit AS, de Bruijn P, Hamberg P, Lam MH, Burger H, Chaves I, Wiemer EA, van der Horst GT, Mathijssen RH.

Clin Pharmacokinet. 2015 Aug;54(8):851-8. doi: 10.1007/s40262-015-0239-5.

27.

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Hamberg P, Mathijssen RH, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, Sleijfer S, Verweij J, de Jonge MJ.

Cancer Chemother Pharmacol. 2015 Feb;75(2):365-71. doi: 10.1007/s00280-014-2655-x. Epub 2014 Dec 23.

PMID:
25533184
28.

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.

Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S.

Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3.

PMID:
25471333
29.

Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.

Diels J, Hamberg P, Ford D, Price PW, Spencer M, Dass RN.

Qual Life Res. 2015 Mar;24(3):591-8. doi: 10.1007/s11136-014-0794-5. Epub 2014 Oct 19.

30.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.

31.

A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.

Dejardin D, Lesaffre E, Hamberg P, Verweij J.

Pharm Stat. 2014 May-Jun;13(3):196-207. doi: 10.1002/pst.1618. Epub 2014 Apr 9.

PMID:
24715683
32.

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.

Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30.

33.

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.

Hamberg P, Boers-Sonderen MJ, van der Graaf WT, de Bruijn P, Suttle AB, Eskens FA, Verweij J, van Herpen CM, Sleijfer S.

Br J Cancer. 2014 Feb 18;110(4):888-93. doi: 10.1038/bjc.2013.798. Epub 2013 Dec 24.

34.

Cyanide intoxication by apricot kernel ingestion as complimentary cancer therapy.

Seghers L, Walenbergh-van Veen M, Salome J, Hamberg P.

Neth J Med. 2013 Nov;71(9):496-8. No abstract available.

35.

Lower tourniquet cuff pressure reduces postoperative wound complications after total knee arthroplasty: a randomized controlled study of 164 patients.

Olivecrona C, Ponzer S, Hamberg P, Blomfeldt R.

J Bone Joint Surg Am. 2012 Dec 19;94(24):2216-21. doi: 10.2106/JBJS.K.01492.

PMID:
23318611
36.

Sunitinib-associated pseudothrombocytopenia induced by IgM antibody.

Albersen A, Porcelijn L, Schilders J, Zuetenhorst H, Njo T, Hamberg P.

Platelets. 2013;24(7):566-70. doi: 10.3109/09537104.2012.731545. Epub 2012 Oct 15.

PMID:
23066976
37.

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI.

Invest New Drugs. 2013 Jun;31(3):751-9. doi: 10.1007/s10637-012-9885-8. Epub 2012 Oct 6.

PMID:
23054212
38.

Effects of CYP induction by rifampicin on tamoxifen exposure.

Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH.

Clin Pharmacol Ther. 2012 Jul;92(1):62-7. doi: 10.1038/clpt.2011.372. Epub 2012 May 23.

PMID:
22617226
39.

Medial Achilles tendon island flap--a novel technique to treat reruptures and neglected ruptures of the Achilles tendon.

Lapidus LJ, Ray BA, Hamberg P.

Int Orthop. 2012 Aug;36(8):1629-34. doi: 10.1007/s00264-012-1521-x. Epub 2012 Mar 17.

40.

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.

Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de Jonge M.

Cancer Chemother Pharmacol. 2011 Sep;68(3):805-13. doi: 10.1007/s00280-011-1693-x. Epub 2011 Jun 26.

41.

Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.

Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG).

Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11.

PMID:
21569996
42.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

43.

Dose-escalation models for combination phase I trials in oncology.

Hamberg P, Ratain MJ, Lesaffre E, Verweij J.

Eur J Cancer. 2010 Nov;46(16):2870-8. doi: 10.1016/j.ejca.2010.07.002. Epub 2010 Aug 4.

PMID:
20691584
44.

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

Hamberg P, Verweij J, Sleijfer S.

Oncologist. 2010;15(6):539-47. doi: 10.1634/theoncologist.2009-0274. Epub 2010 May 28. Review.

45.

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.

Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S.

Br J Cancer. 2010 Jun 8;102(12):1699-706. doi: 10.1038/sj.bjc.6605696. Epub 2010 May 18.

46.
47.

Chemotherapy in patients with castration-resistant prostate cancer.

Meulenbeld HJ, Hamberg P, de Wit R.

Eur J Cancer. 2009 Sep;45 Suppl 1:161-71. doi: 10.1016/S0959-8049(09)70029-2. Review. No abstract available.

PMID:
19775615
48.

Phase I drug combination trial design: walking the tightrope.

Hamberg P, Verweij J.

J Clin Oncol. 2009 Sep 20;27(27):4441-3. doi: 10.1200/JCO.2009.23.6703. Epub 2009 Aug 24. No abstract available.

PMID:
19704054
49.

When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?

Hamberg P, Verhagen PC, de Wit R.

Eur J Cancer. 2008 Jun;44(9):1193-7. doi: 10.1016/j.ejca.2008.04.005. Epub 2008 Apr 28. Review.

PMID:
18448326
50.

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.

Hamberg P, De Jong FA, Brandsma D, Verweij J, Sleijfer S.

Acta Oncol. 2008;47(5):974-8. Review. No abstract available.

PMID:
17924208

Supplemental Content

Loading ...
Support Center